These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1753836)

  • 21. Community-acquired bacteraemia and antibiotic resistance. Trends during a 17-year period in a Danish county.
    Pedersen G; Schønheyder HC; Kristensen B; Sørensen HT
    Dan Med Bull; 2000 Sep; 47(4):296-300. PubMed ID: 11064832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [52-year-old patient with persistent fever despite adequate antibiotic therapy. Infected venous thrombosis].
    Kaasch A; Seifert H
    Dtsch Med Wochenschr; 2010 Jun; 135(23):1175-6. PubMed ID: 20514597
    [No Abstract]   [Full Text] [Related]  

  • 23. Molecular epidemiology of multi-resistant Escherichia coli.
    Guyot A; Barrett SP; Threlfall EJ; Hampton MD; Cheasty T
    J Hosp Infect; 1999 Sep; 43(1):39-48. PubMed ID: 10462638
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended-spectrum beta-lactamases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections.
    Helfand MS; Bonomo RA
    Clin Infect Dis; 2006 Dec; 43(11):1415-6. PubMed ID: 17083013
    [No Abstract]   [Full Text] [Related]  

  • 25. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella.
    Huang SS; Lee MH; Leu HS
    J Microbiol Immunol Infect; 2006 Dec; 39(6):496-502. PubMed ID: 17164953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia.
    Paterson DL; Mulazimoglu L; Casellas JM; Ko WC; Goossens H; Von Gottberg A; Mohapatra S; Trenholme GM; Klugman KP; McCormack JG; Yu VL
    Clin Infect Dis; 2000 Mar; 30(3):473-8. PubMed ID: 10722430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comment on: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Blot S; Vandijck D; Vandewoude K; Depuydt P; Vogelaers D; Peleman R
    J Antimicrob Chemother; 2007 Dec; 60(6):1402. PubMed ID: 17913718
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapeutic modification of Escherichia coli peritonitis and bacteremia by tinospora cordifolia.
    Mathur SK
    J Postgrad Med; 1992; 38(2):102. PubMed ID: 1294124
    [No Abstract]   [Full Text] [Related]  

  • 29. Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome.
    Andersen NF; Møller J; Peterslund NA
    Scand J Infect Dis; 2005; 37(2):90-5. PubMed ID: 15764199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Escherichia coli O157 infections: the Scottish experience.
    Collee JG
    Hosp Med; 1998 Feb; 59(2):164. PubMed ID: 9797897
    [No Abstract]   [Full Text] [Related]  

  • 31. [Microbiology of urinary tract infections in ambulatory patients. Therapeutic options in times of high antibiotic resistance].
    Arreguín V; Cebada M; Simón JI; Sifuentes-Osornio J; Bobadilla-del Valle M; Macías AE
    Rev Invest Clin; 2007; 59(4):239-45. PubMed ID: 18019596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
    Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.
    Wong-Beringer A; Hindler J; Loeloff M; Queenan AM; Lee N; Pegues DA; Quinn JP; Bush K
    Clin Infect Dis; 2002 Jan; 34(2):135-46. PubMed ID: 11740699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia.
    Opal SM; Palardy JE; Parejo N; Jasman RL
    Crit Care Med; 2003 Mar; 31(3):929-32. PubMed ID: 12627007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Escherichia coli a forgotten pathogen in septicemia].
    Sledzińska A; Samet A; Bronk M; Rybak B; Kur J; Krawczyk B; Nowicki B
    Przegl Epidemiol; 2006; 60(1):27-34. PubMed ID: 16758735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Changes in patterns and resistances of bacteria from 731 patients with bacteremia in 11 years].
    Xin J; Xiang Y; Zhang J
    Zhonghua Yi Xue Za Zhi; 1997 May; 77(5):332-5. PubMed ID: 9772485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region.
    Laupland KB; Gregson DB; Church DL; Ross T; Pitout JD
    Clin Microbiol Infect; 2008 Nov; 14(11):1041-7. PubMed ID: 19040476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current status and the development of resistance of important urinary pathogens to antibiotics in the Suhl district 1970-1984].
    Bernasowski A; Kunze M; Metzel D
    Z Gesamte Inn Med; 1986 Aug; 41(16):449-51. PubMed ID: 3095995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbenicillin indanyl sodium oral therapy of urinary tract infections.
    Hodges GR; Perkins RL
    Arch Intern Med; 1973 May; 131(5):679-81. PubMed ID: 4573663
    [No Abstract]   [Full Text] [Related]  

  • 40. [Short communication: comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics].
    Aykut Arca E; Karabiber N
    Mikrobiyol Bul; 2007 Jan; 41(1):115-9. PubMed ID: 17427560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.